Current Oncology Reports

, Volume 9, Issue 2, pp 96–101

Cyclooxygenase-2: A novel target in human solid tumors


DOI: 10.1007/s11912-007-0004-5

Cite this article as:
Raspollini, M.R. & Taddei, G.L. Curr Oncol Rep (2007) 9: 96. doi:10.1007/s11912-007-0004-5


The enzyme cyclooxygenase-2, which is involved in the conversion of arachidonic acid-to-prostanoid synthesis, plays a key role in many inflammatory and proliferative reactions. Experimental data have shown that prostaglandins have a central action in therapeutic targeting not only in the treatment of many inflammatory diseases but also in several types of human cancers. Inhibitors of cyclooxygenase activity seem to protect against carcinoma development and show promise as chemopreventive agents and possible target therapies. Data support new treatments for patients with solid cancers tailored to the molecular characteristics of the individual tumor.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Department of Human Pathology and OncologyUniversity of Florence, School of MedicineFlorenceItaly

Personalised recommendations